Evidence map›Paper›PMID 22864240›Full record

ArticleMolecules (Basel, Switzerland)2012

Synthesis and characterization of new thiazolidinones containing coumarin moieties and their antibacterial and antioxidant activities.

Naceur Hamdi, Abdullah Sulaiman Al-Ayed, Ridha Ben Said, Alary Fabienne

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Naceur HamdiCollege of Science and Arts at Ar-Rass, Qassim University, P.O. Box 53, Saudi Arabia. naceur.hamdi@isste.rnu.tn
Abdullah Sulaiman Al-Ayed
Ridha Ben Said
Alary Fabienne

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New coumarin derivatives, namely (2-(4-methyl-2-oxo-2H-chromen-7-yloxy)-N-(4-oxo-2-phenylthiazolidin-3-yl)acetamide, N-(2-(3-methoxyphenyl)-4-oxothiazolidin-3-yl)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy)acetamide, 2-(4-methyl-2-oxo-2H-chromen-7-yloxy)-N-(4-oxo-2-(2,3,4trimethoxyphenyl)thiazolidin-3-yl)acetamide and N-(2-(4-bromophenyl)-4-oxothiazolidin-3-yl)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy)acetamide) were synthesized starting from 4-methyl-7-hydroxycoumarin. The structures of the obtained compounds were confirmed by analytical IR and NMR spectra to elucidate the different positions of protons and carbons and as well as theoretical studies (DFT/B3LYP). The new compounds were screened for antibacterial activity. Most of them are more active against E. coli S. aureus and B. subtilis than standard references.

Indexed as

Anti-Bacterial AgentsBacillus megateriumBenzothiazolesBiphenyl CompoundsComputer SimulationCoumarinsDisk Diffusion Antimicrobial TestsEscherichia coliFree RadicalsFree Radical ScavengersMagnetic Resonance SpectroscopyModels, MolecularMolecular ConformationPicratesProteus vulgarisQuantum Theory1,1-diphenyl-2-picrylhydrazyl2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acidAnti-Bacterial AgentsBenzothiazolesBiphenyl CompoundsCoumarinsFree RadicalsFree Radical ScavengersPicratesSulfonic AcidsThiazolidinediones

Identifiers

PMID22864240
PMCPMC6268791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.